Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...
Native Orthopaedics has earned FDA clearance for its Native root system powered by Dragonfly technology for meniscus root ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback